Friday, October 30, 2026

Less Than Five Hours Before The Market Open, SmileDirectClub Is Up By 13%

Less Than Five Hours Before The Market Open, SmileDirectClub Is Up By 13%

(VIANEWS) - The NASDAQ opens in less than five hours and SmileDirectClub's pre-market value is already 13.75% up.

SmileDirectClub's last close was $0.40, 82.3% below its 52-week high of $2.26.

The last session, NASDAQ finished with SmileDirectClub (SDC) jumping 2.54% to $0.40. NASDAQ slid 0.63% to $12,179.55, following the last session's downward trend on what was a somewhat bearish trend exchanging session.

About SmileDirectClub

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

Revenue Growth

Year-on-year quarterly revenue growth declined by 31.5%, now sitting on 470.74M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SmileDirectClub's EBITDA is -15.84.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is 31.6% and 35.3%, respectively.

Sales Growth

SmileDirectClub's sales growth is negative 29.3% for the ongoing quarter and negative 16.3% for the next.

More news about SmileDirectClub (SDC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com